Key result
Efsubaglutide alfa increased acute heart rate and intrinsic heart rate compared with untreated SND in rats.
Why the study?
Pacemaker therapy does not reverse sinoatrial node injury in sinoatrial node dysfunction, and whether long-acting GLP-1 receptor agonists can repair an injured sinoatrial node remained unknown.
Does long-acting GLP-1 receptor agonism with efsubaglutide alfa improve sinoatrial node function and attenuate electrophysiological and structural remodeling in preclinical models of sinoatrial node dysfunction?
Does long-acting GLP-1 receptor agonism with efsubaglutide alfa improve sinoatrial node function and attenuate electrophysiological and structural remodeling in preclinical models of sinoatrial node dysfunction?
In preclinical rodent models of diabetes-related sinoatrial node dysfunction, the long-acting GLP-1 receptor agonist efsubaglutide alfa reverses electrophysiological and structural sinoatrial node remodeling independently of glucose lowering.
Answers are grounded in this paper and cite their sources.
Efsubaglutide alfa may restore sinoatrial node function in diabetic rats; hypothesis-generating for GLP-1RA effects in human SND, requiring clinical trials.
Background: Sinoatrial node dysfunction (SND) causes bradyarrhythmia, while pacemaker therapy does not reverse injury to the sinoatrial node (SAN). Long-acting GLP-1 receptor agonists (GLP-1RAs) raise heart rate, but whether they can repair an injured SAN in SND remains unknown. Methods: In streptozotocin-induced SND rats, we studied an acute phase (SND, GLP-1RA treatment, glycemic control, and GLP-1R antagonist groups) and a chronic phase (SND, GLP-1RA treatment, and glycemic control groups). Endpoints included heart rate, RR interval, heart rate variability, intrinsic heart rate (IHR), corrected sinus node recovery time after adenosine injection (ADSNRT), SAN transcriptomics, histology and immunofluorescence, HL-1 cell oxidative-stress studies, and public single-cell data. Results: At the acute endpoint, the long-acting GLP-1RA efsubaglutide alfa (eSuba) increased heart rate (372.76 ± 11.06 vs 312.64 ± 22.28 beats/min; P < 0.0001) and IHR (349.45 ± 10.49 vs 234.79 ± 12.29 beats/min; P < 0.0001), and shortened ADSNRT (4.22 ± 2.75 vs 20.68 ± 1.60 s; P = 0.0009); improvements in heart rate (349.05 ± 17.73 vs 266.02 ± 13.52 beats/min; P < 0.0001) and IHR persisted in the chronic phase. SAN transcriptomics showed reversal of extracellular matrix, inflammatory/immune, redox/mitochondrial, glial, and electrical programs. The GLP-1RA reduced collagen deposition and CCR2a+ infiltration, decreased ox-CaMKII/CaMKII, increased SIRT3, restored Cav1.3, Nav1.5, SERCA2a and p-RyR2 (Ser2808), and increased p-PKA/PKA. The glycemic control comparator produced limited improvement, and the GLP-1R antagonist attenuated most effects. Conclusions: Long-acting GLP-1R agonism improves SAN function in SND via glucose-independent attenuation of electrophysiological and structural remodeling, an effect that is at least partly GLP-1R dependent.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Streptozotocin-induced sinoatrial node dysfunction (SND). Efsubaglutide alfa (eSuba) vs. Untreated SND control, insulin glargine (glycemic control), and eSuba + exendin 9-39 (GLP-1R antagonist) was evaluated on Mean heart rate at the acute endpoint (beats/min) (p=<0.0001). Efsubaglutide alfa increased acute heart rate and intrinsic heart rate compared with untreated SND in rats.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: